Shukra Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 29 May 2024, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Shukra Pharmaceuticals rose 0.25% to Rs 3.99 crore in the quarter ended March 2024 as against Rs 3.98 crore during the previous quarter ended March 2023. Sales declined 76.48% to Rs 10.88 crore in the quarter ended March 2024 as against Rs 46.25 crore during the previous quarter ended March 2023.For the full year,net profit rose 320.41% to Rs 18.54 crore in the year ended March 2024 as against Rs 4.41 crore during the previous year ended March 2023. Sales rose 26.76% to Rs 74.57 crore in the year ended March 2024 as against Rs 58.83 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales10.8846.25 -76 74.5758.83 27 OPM %40.817.91 -26.029.13 - PBDT5.754.48 28 21.936.29 249 PBT5.233.97 32 19.884.45 347 NP3.993.98 0 18.544.41 320 Powered by Capital Market - Live News

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2024Powered by Capital Market - Live News

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 March 2024.Powered by Capital Market - Live News

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 February 2024.Powered by Capital Market - Live News